Safety, Tolerability and Effectiveness of Natalizumab in Adolescents With Active Crohn's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

May 31, 2004

Study Completion Date

May 31, 2004

Conditions
Crohn's Disease
Interventions
DRUG

natalizumab

Trial Locations (13)

14642

University of Rochester, Rochester

17033

Hershey Medical Center, Hershey

28211

Carolina Digestive Health Associates, Charlotte

33173

Miami Research Associates, Miami

53226

Medical College of Wisconsin, Milwaukee

90048

Cedars-Sinai IBD Center, Los Angeles

06106

Connecticut Children's Medical Center, Hartford

21287-2631

Johns Hopkins University School of Medicine, Baltimore

02114

Mass General Hospital for Children, Pediatric GI & Nutrition, Boston

02115

The Children's Hospital, Boston

19104-4399

Children's Hospital of Philadelphia, Philadelphia

EH9 1LF

Royal Hospital for Sick Children, Edinburgh

NWS 2QG

Royal Free Medical School, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Elan Pharmaceuticals

INDUSTRY

lead

Biogen

INDUSTRY